NeoGenomics Inc (NEO)-医療機器分野:企業M&A・提携分析

◆英語タイトル:NeoGenomics Inc (NEO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011509
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular genetics including sanger sequencing and fragment analysis. It also offers APvX, LIS/EMR integration and tech-only services. NeoGenomics’s biopharma services support drug development programs ranging from early biomarker discovery to clinical trials. The company caters to oncologists, pathologists, pharmaceutical companies, academic centers, and others. It operates through its subsidiaries. NeoGenomics is headquartered in Fort Myers, Florida, the US.

NeoGenomics Inc (NEO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NeoGenomics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
NeoGenomics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
NeoGenomics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
NeoGenomics Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
NeoGenomics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
NeoGenomics Inc, Medical Equipment, Deal Details 11
Partnerships 11
Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 11
Health Discovery Enters Into Licensing Agreement With NeoGenomics 12
NeoGenomics and Definiens Enter into Agreement 13
Arno Therapeutics Enters Into Co-Development Agreement With Clarient Diagnostic Services 14
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 15
Biocept Enters Into Co-Marketing Agreement With Clarient 16
Signal Genetics Enters Into Co-Marketing Agreement With NeoGenomics 17
CombiMatrix Enters Into An Agreement With Clarient 18
Equity Offering 19
NeoGenomics Raises USD37 Million in Public Offering of Shares 19
NeoGenomics Completes Public Offering Of Shares For US$10 Million 21
NeoGenomics Completes Private Placement Of Common Stock For US$3 Million 22
Acquisition 23
NeoGenomics Acquires Clarient from GE Healthcare 23
GE Healthcare Completes Acquisition Of Clarient 25
NeoGenomics Inc – Key Competitors 27
NeoGenomics Inc – Key Employees 28
NeoGenomics Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 31
Strategy And Business Planning 31
Nov 09, 2017: NeoGenomics Europe Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials 31
Financial Announcements 32
Jul 25, 2017: NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 32
Apr 26, 2017: NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 34
Feb 22, 2017: NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 36
Oct 26, 2016: NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016 38
Jul 26, 2016: NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016 40
Apr 27, 2016: NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains 42
Mar 01, 2016: NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains 44
Corporate Communications 46
Apr 20, 2017: NeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development 46
Product News 47
Jun 02, 2017: NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
NeoGenomics Inc, Medical Equipment, Key Facts, 2016 2
NeoGenomics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
NeoGenomics Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
NeoGenomics Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
NeoGenomics Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
NeoGenomics Inc, Deals By Market, 2011 to YTD 2017 9
NeoGenomics Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 11
Health Discovery Enters Into Licensing Agreement With NeoGenomics 12
NeoGenomics and Definiens Enter into Agreement 13
Arno Therapeutics Enters Into Co-Development Agreement With Clarient Diagnostic Services 14
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 15
Biocept Enters Into Co-Marketing Agreement With Clarient 16
Signal Genetics Enters Into Co-Marketing Agreement With NeoGenomics 17
CombiMatrix Enters Into An Agreement With Clarient 18
NeoGenomics Raises USD37 Million in Public Offering of Shares 19
NeoGenomics Completes Public Offering Of Shares For US$10 Million 21
NeoGenomics Completes Private Placement Of Common Stock For US$3 Million 22
NeoGenomics Acquires Clarient from GE Healthcare 23
GE Healthcare Completes Acquisition Of Clarient 25
NeoGenomics Inc, Key Competitors 27
NeoGenomics Inc, Key Employees 28
NeoGenomics Inc, Other Locations 29
NeoGenomics Inc, Subsidiaries 30

★海外企業調査レポート[NeoGenomics Inc (NEO)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Booster Juice Ltd:企業の戦略・SWOT・財務情報
    Booster Juice Ltd - Strategy, SWOT and Corporate Finance Report Summary Booster Juice Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Ig Group Holdings Plc
    Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Ig Group Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Windtree Therapeutics Inc (WINT):医療機器:M&Aディール及び事業提携情報
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …
  • NETGEAR Inc. (NTGR):企業の財務・戦略的SWOT分析
    NETGEAR Inc. (NTGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Banyan Biomarkers Inc:企業の製品パイプライン分析2018
    Summary Banyan Biomarkers Inc (Banyan Biomarkers) is a medical technology company that commercializes vitro diagnostic tests for the detection of traumatic brain injury and neurological diseases. The company’s product pipeline includes biomarkers for depression, hypoxic ischemic encephalopathy, neur …
  • Space Hellas S.A. (SPACE):企業の財務・戦略的SWOT分析
    Space Hellas S.A. (SPACE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • St. Augustine Gold and Copper Limited:企業の戦略・SWOT・財務情報
    St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report Summary St. Augustine Gold and Copper Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Antero Resources Corp (AR):石油・ガス:M&Aディール及び事業提携情報
    Summary Antero Resources Corp (Antero) is an independent oil and natural gas company that explores, develops, produces and sells natural gas and oil from the Appalachia Basin. It gather and process wellhead natural gas and produce natural gas liquids (NGLs). The company also purchases and sells thir …
  • Sinovel Wind Group Co Ltd (601558):企業の財務・戦略的SWOT分析
    Summary Sinovel Wind Group Co Ltd (Sinovel) is a wind turbine manufacturing company. The company designs, manufactures, develops, and commercializes the large-scale of onshore, offshore and intertidal wind turbines. Its products include SL1500 series wind turbines, SL2000 series wind turbines, SL300 …
  • Dassault Aviation SA (AM):企業の財務・戦略的SWOT分析
    Dassault Aviation SA (AM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oncternal Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncternal Therapeutics Inc (Oncternal), formerly Tokalas, Inc., is a clinical-stage oncology company which focuses on the development of therapies for rare and common cancers. Its pipeline compound portfolio includes cirmtuzumab and TK216. The company’s pipeline compounds are primarily focus …
  • Airvolution Energy Limited:電力:M&Aディール及び事業提携情報
    Summary Airvolution Energy Limited (Airvolution) a subsidiary of Electricity Supply Board, is a renewable energy company that develops, construct and operate small onshore wind projects. It provides landowners a secure, long term revenue stream and takes all the financial risk during development of …
  • China High Speed Transmission Equipment Group Co Ltd (658):企業の財務・戦略的SWOT分析
    China High Speed Transmission Equipment Group Co Ltd (658) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the compa …
  • Oneok Inc (OKE):企業の財務・戦略的SWOT分析
    Oneok Inc (OKE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Mytilineos Holdings Sa
    Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report Summary Mytilineos Holdings Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Lin Bioscience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Lin Bioscience Inc (Lin Bioscience) is a drug development company that specializes in developing therapies for oncology, ophthalmology and other metabolic diseases. The company’s pipeline product LBS-008 is an oral therapy for treatment of macular degeneration; LBS-007 is a small molecular i …
  • Exelixis Inc (EXEL)-製薬・医療分野:企業M&A・提携分析
    Summary Exelixis Inc (Exelixis) is a biopharmaceutical company focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has three product candidates: Cometriq (Cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (c …
  • ZIOPHARM Oncology Inc (ZIOP):企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • SBS Transit Ltd.:戦略・SWOT・企業財務分析
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Swedish Orphan Biovitrum AB (SOBI):企業の財務・戦略的SWOT分析
    Swedish Orphan Biovitrum AB (SOBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆